{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:02:39Z","timestamp":1790960559251,"version":"4.1.0"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.blre.2025.101257","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T07:26:35Z","timestamp":1736580395000},"page":"101257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Application of thrombopoietic agents in cancer therapy-induced thrombocytopenia: A comprehensive review"],"prefix":"10.1016","volume":"70","author":[{"given":"Junyang","family":"Mei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiujie","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2025.101257_bb0005","first-page":"203","article-title":"Progress in application of platelet stimulating agents in management of cancer therapy-related thrombocytopenia","volume":"42","author":"Wang","year":"2022","journal-title":"Tumor"},{"issue":"103","key":"10.1016\/j.blre.2025.101257_bb0010","first-page":"2579","article-title":"Committee of Neoplastic Supportive-Care, China Anti-Cancer Association. [Consensus on the clinical diagnosis, treatment and prevention of cancer treatment-induced thrombocytopenia in China (2023 edition)]","author":"Society of Chemotherapy","year":"2023","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.blre.2025.101257_bb0015","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3389\/fimmu.2019.00523","article-title":"Antigenic mimicry in paraneoplastic immune thrombocytopenia","volume":"10","author":"Vial","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101257_bb0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.critrevonc.2011.02.004","article-title":"Paraneoplastic autoimmune thrombocytopenia in solid tumors","volume":"81","author":"Krauth","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2025.101257_bb0025","first-page":"CD012035","article-title":"Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours","volume":"11","author":"Zhang","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.blre.2025.101257_bb0030","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S1470-2045(19)30026-9","article-title":"Immunotherapy and targeted therapy combinations in metastatic breast cancer","volume":"20","author":"Esteva","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2025.101257_bb0035","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/17474086.2021.1924053","article-title":"Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia","volume":"14","author":"Al-Samkari","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2025.101257_bb0040","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/17474086.2023.2201428","article-title":"Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia","volume":"16","author":"Song","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2025.101257_bb0045","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12885-019-5354-5","article-title":"Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice","volume":"19","author":"Weycker","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.blre.2025.101257_bb0050","first-page":"307","article-title":"Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review","volume":"16","author":"Depr\u00e9","year":"2018","journal-title":"Blood Transfus Trasfus Sangue"},{"key":"10.1016\/j.blre.2025.101257_bb0055","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1200\/JCO.2001.19.4.1137","article-title":"Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia","volume":"19","author":"Elting","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101257_bb0060","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.6004\/jnccn.2015.0166","article-title":"Dose delays, dose reductions, and relative dose intensity in patients with Cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices","volume":"13","author":"Denduluri","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.blre.2025.101257_bb0065","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2147\/DDDT.S299591","article-title":"A review of Romiplostim mechanism of action and clinical applicability","volume":"15","author":"Bussel","year":"2021","journal-title":"Drug Des Devel Ther"},{"issue":"Pt 2","key":"10.1016\/j.blre.2025.101257_bb0070","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.clinthera.2009.11.020","article-title":"Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007","volume":"31","author":"Wu","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.blre.2025.101257_bb0075","article-title":"A real-world observation of Eltrombopag and recombinant human Thrombopoietin (rhTPO) in lymphoma patients with chemotherapy induced thrombocytopenia","volume":"11","author":"Zhu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2025.101257_bb0080","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10549-013-2582-2","article-title":"A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting","volume":"139","author":"Lyman","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.blre.2025.101257_bb0085","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.21037\/apm-22-880","article-title":"Cost-effectiveness analysis of rhTPO and rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia in hematological tumors based on real-world data","volume":"11","author":"Zhang","year":"2022","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.blre.2025.101257_bb0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12885-019-5354-5","article-title":"Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice","volume":"19","author":"Weycker","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.blre.2025.101257_bb0095","first-page":"1","article-title":"The clinical efficacy and economic benefits of recombinant human Thrombopoietin for the treatment of chemotherapy or Chemoradiotherapy-induced thrombocytopenia. Hashmi MF, editor","volume":"2022","author":"Wang","year":"2022","journal-title":"Contrast Media Mol Imaging"},{"key":"10.1016\/j.blre.2025.101257_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100909","article-title":"The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag","volume":"53","author":"Kuter","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2025.101257_bb0105","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/17474086.2021.1924053","article-title":"Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia","volume":"14","author":"Al-Samkari","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2025.101257_bb0110","series-title":"Avatrombopag: A Review in Thrombocytopenia Drugs","first-page":"1905","volume":"81","author":"Markham","year":"2021"},{"key":"10.1016\/j.blre.2025.101257_bb0115","first-page":"CD004269","article-title":"Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation","author":"Estcourt","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.blre.2025.101257_bb0120","article-title":"Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation","volume":"2016","author":"Desborough","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.blre.2025.101257_bb0125","first-page":"623","article-title":"Value of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor","volume":"30","author":"Dai","year":"2008","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.blre.2025.101257_bb0130","first-page":"207","article-title":"Impact on platelet recovery of recombinant human thrombopoietin in severe aplastic anemia patients with allogeneic hematopoietic stem cell transplantation","volume":"39","author":"Song","year":"2018","journal-title":"Zhonghua Xue Ye Xue Za Zhi Zhonghua Xueyexue Zazhi"},{"key":"10.1016\/j.blre.2025.101257_bb0135","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1080\/10428194.2018.1459605","article-title":"Recombinant human thrombopoietin (rh-TPO) for the prevention of severe thrombocytopenia induced by high-dose cytarabine: a prospective, randomized, self-controlled study","volume":"59","author":"Wang","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2025.101257_bb0140","first-page":"948","article-title":"Expert consensus on rational use of recombinant human IL-11 for thrombocytopenia in solid tumor patients","volume":"32","year":"2010","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.blre.2025.101257_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257673","article-title":"Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia","volume":"17","author":"Soff","year":"2022","journal-title":"PloS One"},{"key":"10.1016\/j.blre.2025.101257_bb0150","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.7150\/jca.26690","article-title":"A randomized controlled study of rhTPO and rhIL-11 for the prophylactic treatment of chemotherapy-induced thrombocytopenia in non-small cell lung Cancer","volume":"9","author":"Xu","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.blre.2025.101257_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101139","article-title":"Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists","volume":"63","author":"Al-Samkari","year":"2024","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2025.101257_bb0160","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3390\/jcm10061169","article-title":"Challenges and advances in managing thrombocytopenic Cancer patients","volume":"10","author":"Leader","year":"2021","journal-title":"J Clin Med"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2025.101257_bb0165","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S0049-3848(14)50011-4","article-title":"Thrombocytopenia in cancer patients","volume":"133","author":"Liebman","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2025.101257_bb0170","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3324\/haematol.2021.279512","article-title":"Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies","volume":"107","author":"Kuter","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101257_bb0175","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2165\/11594310-000000000-00000","article-title":"Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital-based cohort study","volume":"34","author":"Ten Berg","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.blre.2025.101257_bb0180","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/1078155210380293","article-title":"Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors","volume":"17","author":"Hitron","year":"2011","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"key":"10.1016\/j.blre.2025.101257_bb0185","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/ejh.13595","article-title":"The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies","volume":"106","author":"Shaw","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101257_bb0190","doi-asserted-by":"crossref","first-page":"e18911","DOI":"10.1200\/JCO.2018.36.15_suppl.e18911","article-title":"Risk and cost of chemotherapy-induced thrombocytopenia (CIT) in US clinical practice","volume":"36","author":"Weycker","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101257_bb0195","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.927008","article-title":"Avatrombopag optimizes response to Niraparib by managing thrombocytopenia associated with poly-ADP ribose polymerase (PARP) inhibition in ovarian Cancer and breast Cancer: a case series","volume":"21","author":"Gabrail","year":"2020","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.blre.2025.101257_bb0200","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.21037\/atm-21-2763","article-title":"Assessment of racial differences in the incidence of thrombocytopenia induced by trastuzumab emtansine: a systematic review and meta-analysis","volume":"9","author":"Zhang","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.blre.2025.101257_bb0205","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s13287-020-01861-x","article-title":"Mitigative efficacy of the clinical dosage administration of granulocyte colony-stimulating factor and romiplostim in mice with severe acute radiation syndrome","volume":"11","author":"Yamaguchi","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.blre.2025.101257_bb0210","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00262-021-03068-2","article-title":"Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival","volume":"71","author":"Haddad","year":"2022","journal-title":"Cancer Immunol Immunother CII"},{"key":"10.1016\/j.blre.2025.101257_bb0215","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-235249","article-title":"Rare case of life-threatening thrombocytopenia occurring after radiotherapy in a patient treated with immune checkpoint inhibitor","volume":"13","author":"Hendrix","year":"2020","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.blre.2025.101257_bb0220","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and Meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.blre.2025.101257_bb0225","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/369533a0","article-title":"Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand","volume":"369","author":"de Sauvage","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.blre.2025.101257_bb0230","doi-asserted-by":"crossref","first-page":"11104","DOI":"10.1073\/pnas.91.23.11104","article-title":"The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production","volume":"91","author":"Kuter","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2025.101257_bb0235","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/0092-8674(94)90450-2","article-title":"Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl","volume":"77","author":"Bartley","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.blre.2025.101257_bb0240","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1159\/000205503","article-title":"Demonstration and some properties of human thrombopoietin in thrombocythaemic sera","volume":"20","author":"Kelemen","year":"1958","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2025.101257_bb0245","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40265-021-01553-7","article-title":"Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists","volume":"81","author":"Gilreath","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.blre.2025.101257_bb0250","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/0092-8674(90)90410-G","article-title":"A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors","volume":"63","author":"Souyri","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.blre.2025.101257_bb0255","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1073\/pnas.89.12.5640","article-title":"Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily","volume":"89","author":"Vigon","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2025.101257_bb0260","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bjh.12781","article-title":"Milestones in understanding platelet production: a historical overview","volume":"165","author":"Kuter","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101257_bb0265","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1182\/blood-2006-10-019315","article-title":"New thrombopoietic growth factors","volume":"109","author":"Kuter","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101257_bb0270","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM199809103391107","article-title":"Thrombopoietin","volume":"339","author":"Kaushansky","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101257_bb0275","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1172\/JCI26674","article-title":"The molecular mechanisms that control thrombopoiesis","volume":"115","author":"Kaushansky","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2025.101257_bb0280","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter","year":"2015","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.blre.2025.101257_bb0285","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood.V87.6.2154.bloodjournal8762154","article-title":"Regulation of Thrombopoietin levels by c-mpl\u2013mediated binding to platelets","volume":"87","author":"Fielder","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101257_bb0290","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/bjh.12328","article-title":"Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside","volume":"161","author":"Deutsch","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101257_bb0295","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1111\/jcmm.13809","article-title":"Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist","volume":"22","author":"Xie","year":"2018","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.blre.2025.101257_bb0300","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/blood.V100.10.3457","article-title":"Recombinant human thrombopoietin: basic biology and evaluation of clinical studies","volume":"100","author":"Kuter","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101257_bb0305","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev.med.60.042307.181154","article-title":"Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia","volume":"60","author":"Kuter","year":"2009","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.blre.2025.101257_bb0310","article-title":"Recombinant human thrombopoietin promotes platelet recovery in DCAG-treated patients with intermediate-high-risk MDS\/hypoproliferative AML","volume":"102","author":"Chen","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.blre.2025.101257_bb0315","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231152746","article-title":"Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia","volume":"14","author":"Huang","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2025.101257_bb0320","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"Kuter","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2025.101257_bb0325","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood.V85.10.2720.bloodjournal85102720","article-title":"The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit","volume":"85","author":"Kuter","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101257_bb0330","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood.V87.2.567.bloodjournal872567","article-title":"Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets","volume":"87","author":"Stoffel","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101257_bb0335","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.exphem.2008.02.012","article-title":"Transcriptional regulation of bone marrow thrombopoietin by platelet proteins","volume":"36","author":"McIntosh","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2025.101257_bb0340","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1046\/j.1365-2141.1996.d01-1702.x","article-title":"Circulating thrombopoietin level in chronic immune thrombocytopenic purpura","volume":"93","author":"Kosugi","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101257_bb0345","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1055\/s-0038-1650545","article-title":"Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenic purpura","volume":"76","author":"Ichikawa","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101257_bb0350","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0002-9343(98)00090-4","article-title":"Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis","volume":"104","author":"Wang","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2025.101257_bb0355","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s002770050445","article-title":"High levels of thrombopoietin in sera of patients with essential thrombocythemia: cause or consequence of abnormal platelet production?","volume":"77","author":"Griesshammer","year":"1998","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2025.101257_bb0360","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nm.3770","article-title":"The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling","volume":"21","author":"Grozovsky","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2025.101257_bb0365","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1016\/j.cell.2023.07.037","article-title":"Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis","volume":"186","author":"Tsutsumi","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.blre.2025.101257_bb0370","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"Li","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101257_bb0375","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.V99.7.2599","article-title":"Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor","volume":"99","author":"Basser","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101257_bb0380","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000355006","article-title":"Clinical indications for thrombopoietin and thrombopoietin-receptor agonists","volume":"40","author":"W\u00f6rmann","year":"2013","journal-title":"Transfus Med Hemotherapy Off Organ Dtsch Ges Transfusionsmedizin Immunhamatologie"},{"key":"10.1016\/j.blre.2025.101257_bb0385","doi-asserted-by":"crossref","first-page":"10","DOI":"10.15252\/emmm.201708450","article-title":"Thrombopoietin: tickling the HSC\u2019s fancy","volume":"10","author":"Kim","year":"2018","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.blre.2025.101257_bb0390","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.5114\/aoms\/141134","article-title":"Prophylactic administration of recombinant human thrombopoietin attenuates XELOX or SOX regimen-induced thrombocytopaenia","volume":"17","author":"Li","year":"2021","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.blre.2025.101257_bb0395","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7326\/0003-4819-132-5-200003070-00005","article-title":"Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer","volume":"132","author":"Vadhan-Raj","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2025.101257_bb0400","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cyto.2017.02.012","article-title":"Thrombopoietin contributes to the formation and the maintenance of hematopoietic progenitor-containing cell clusters in the aorta-gonad-mesonephros region","volume":"95","author":"Harada","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.blre.2025.101257_bb0405","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2003.08.003","article-title":"Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia","volume":"21","author":"Vadhan-Raj","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101257_bb0410","first-page":"437","article-title":"A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor","volume":"26","author":"Bai","year":"2004","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"10.1016\/j.blre.2025.101257_bb0415","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cyto.2003.05.001","article-title":"AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl","volume":"25","author":"Broudy","year":"2004","journal-title":"Cytokine"},{"key":"10.1016\/j.blre.2025.101257_bb0420","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/bjh.16658","article-title":"Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry","volume":"190","author":"Mytych","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101257_bb0425","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1749-6632.2011.05975.x","article-title":"The development of romiplostim for patients with immune thrombocytopenia","volume":"1222","author":"Molineux","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.blre.2025.101257_bb0430","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3324\/haematol.2016.146746","article-title":"Revealing eltrombopag\u2019s promotion of human megakaryopoiesis through AKT\/ERK-dependent pathway activation","volume":"101","author":"Di Buduo","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101257_bb0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054723","article-title":"High doses of romiplostim induce proliferation and reduce proplatelet formation by human megakaryocytes","volume":"8","author":"Currao","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.blre.2025.101257_bb0440","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3324\/haematol.2016.153668","article-title":"Eltrombopag, a potent stimulator of megakaryopoiesis","volume":"101","author":"Raslova","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101257_bb0445","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1021\/jm025535c","article-title":"Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics","volume":"45","author":"Duffy","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2025.101257_bb0450","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1021\/jm010283l","article-title":"Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis","volume":"44","author":"Duffy","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2025.101257_bb0455","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101257_bb0460","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/JBM.S191790","article-title":"Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease","volume":"10","author":"Cheloff","year":"2019","journal-title":"J Blood Med"},{"key":"10.1016\/j.blre.2025.101257_bb0465","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1182\/blood.V104.11.2909.2909","article-title":"Species specificity and receptor domain interaction of a small molecule TPO receptor agonist","volume":"104","author":"Erickson-Miller","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101257_bb0470","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.exphem.2004.09.006","article-title":"Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist","volume":"33","author":"Erickson-Miller","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2025.101257_bb0475","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0609.2008.01198.x","article-title":"AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist","volume":"82","author":"Fukushima-Shintani","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101257_bb0480","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjh.15574","article-title":"Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled phase 1 studies","volume":"183","author":"Kuter","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101257_bb0485","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40265-015-0525-4","article-title":"Lusutrombopag: first global approval","volume":"76","author":"Kim","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.blre.2025.101257_bb0490","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/bcp.14259","article-title":"Effect of postdose fasting duration on hetrombopag olamine pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"86","author":"Yang","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.blre.2025.101257_bb0495","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s40265-021-01575-1","article-title":"Hetrombopag: first approval","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.blre.2025.101257_bb0500","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim treatment of chemotherapy-induced thrombocytopenia","volume":"37","author":"Soff","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101257_bb0505","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3324\/haematol.2020.251900","article-title":"A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101257_bb0510","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/cncr.27772","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States","volume":"119","author":"Khorana","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2025.101257_bb0515","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.beha.2008.12.001","article-title":"Epidemiology of cancer-related venous thromboembolism","volume":"22","author":"Wun","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2025.101257_bb0520","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12885-023-10975-3","article-title":"Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia","volume":"23","author":"Shin","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.blre.2025.101257_bb0525","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2022.0026","article-title":"NCCN guidelines\u00ae insights: hematopoietic growth factors, version 1.2022: featured updates to the NCCN guidelines","volume":"20","author":"Griffiths","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.blre.2025.101257_bb0530","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1080\/09537104.2022.2117293","article-title":"Romiplostim for PARP inhibitor-induced thrombocytopenia in solid tumor malignancies","volume":"33","author":"Cheloff","year":"2022","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2025.101257_bb0535","first-page":"oyad185","article-title":"Thrombopoietin receptor agonists for thrombocytopenia secondary to HER2-targeted antibody drug conjugates","author":"Rainone","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.blre.2025.101257_bb0540","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s12185-017-2319-9","article-title":"Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study","volume":"106","author":"Winer","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2025.101257_bb0545","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S2352-3026(17)30228-4","article-title":"Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial","volume":"5","author":"Mittelman","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101257_bb0550","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.3324\/haematol.2020.260125","article-title":"The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis","volume":"106","author":"Shoukier","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101257_bb0555","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.lungcan.2020.05.015","article-title":"Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient","volume":"146","author":"Ito","year":"2020","journal-title":"Lung Cancer Amst Neth"},{"key":"10.1016\/j.blre.2025.101257_bb0560","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2152\/jmi.70.516","article-title":"A case of successful treatment with eltrombopag for severe immune-related thrombocytopenia induced by atezolizumab:Case report","volume":"70","author":"Harada","year":"2023","journal-title":"J Med Invest"},{"key":"10.1016\/j.blre.2025.101257_bb0565","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11060-011-0675-5","article-title":"Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient","volume":"106","author":"Duic","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1016\/j.blre.2025.101257_bb0570","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/S2352-3026(22)00001-1","article-title":"Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Al-Samkari","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101257_bb0575","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.970978","article-title":"Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: a multicenter, open-label, single-arm trial","volume":"13","author":"Cui","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.blre.2025.101257_bb0580","article-title":"Case report: successful Avatrombopag treatment for two cases of anti-PD-1 antibody-induced acquired Amegakaryocytic thrombocytopenia","volume":"12","author":"Tu","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.blre.2025.101257_bb0585","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241260985","article-title":"Hetrombopag for the management of chemotherapy-induced thrombocytopenia in patients with advanced solid tumors: a multicenter, randomized, double-blind, placebo-controlled, phase II study","volume":"16","author":"Qin","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.blre.2025.101257_bb0590","first-page":"397","article-title":"The clinical study of recombinant human thrombopoietin in the treatment of chemotherapy-induced severe thrombocytopenia","volume":"84","author":"Bai","year":"2004","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.blre.2025.101257_bb0595","first-page":"623","article-title":"Value of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor","volume":"30","author":"Dai","year":"2008","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.blre.2025.101257_bb0600","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood.V95.8.2530","article-title":"A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia","volume":"95","author":"Schiffer","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101257_bb0605","doi-asserted-by":"crossref","first-page":"e513","DOI":"10.1097\/MJT.0000000000001331","article-title":"Prophylactic Administration of Recombinant Human Thrombopoietin in the secondary prevention of thrombocytopenia induced by XELOX adjuvant chemotherapy in patients with stage III colorectal Cancer","volume":"28","author":"Jin","year":"2021","journal-title":"Am J Ther"},{"key":"10.1016\/j.blre.2025.101257_bb0610","first-page":"395","article-title":"Short-term intermittent prophylactic administration of recombinant human thrombopoietin attenuates chemotherapy-induced thrombocytopenia in lung cancer patients","volume":"33","author":"Xu","year":"2011","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.blre.2025.101257_bb0615","doi-asserted-by":"crossref","first-page":"e19532","DOI":"10.1200\/jco.2014.32.15_suppl.e19532","article-title":"Prevention of thrombocytopenia using thrombopoietin in high-dose cytarabine treatment of non-Hodgkin lymphoma","volume":"32","author":"Huang","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101257_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102231","article-title":"Hetrombopag plus recombinant human thrombopoietin for chemotherapy-induced thrombocytopenia in patients with solid tumors","volume":"7","author":"Xia","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101257_bb0625","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.ijrobp.2020.07.2325","article-title":"Single-dose Administration of Recombinant Human Thrombopoietin Mitigates Total Body Irradiation-Induced Hematopoietic System Injury in mice and nonhuman Primates","volume":"108","author":"Xing","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.blre.2025.101257_bb0630","first-page":"1953","article-title":"rhTPO ameliorates radiation-induced long-term hematopoietic stem cell injury in mice","volume":"28","author":"Luan","year":"2023","journal-title":"Mol Basel Switz"},{"key":"10.1016\/j.blre.2025.101257_bb0635","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12185-012-1124-8","article-title":"A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia","volume":"96","author":"Wang","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2025.101257_bb0640","article-title":"A real-world observation of Eltrombopag and recombinant human Thrombopoietin (rhTPO) in lymphoma patients with chemotherapy induced thrombocytopenia","volume":"11","author":"Zhu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2025.101257_bb0645","first-page":"65","article-title":"Chinese expert consensus on prevention and treatment of chemotherapy-induced thrombocytopenia in malignant lymphoma","volume":"29","author":"Alliance","year":"2020","journal-title":"J Leuk Lymphoma"},{"issue":"103","key":"10.1016\/j.blre.2025.101257_bb0650","first-page":"2579","article-title":"Edition","volume":"2023","author":"Society of Chemotherapy","year":"2023","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.blre.2025.101257_bb0655","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jtha.2023.09.031","article-title":"Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH subcommittee on hemostasis and malignancy","volume":"22","author":"Soff","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101257_bb0660","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/14656566.2020.1841748","article-title":"An evaluation of avatrombopag for the treatment of thrombocytopenia","volume":"22","author":"Virk","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.blre.2025.101257_bb0665","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/cancers10080271","article-title":"The role of direct Oral anticoagulants in treatment of Cancer-associated thrombosis","volume":"10","author":"Al-Samkari","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2025.101257_bb0670","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/ATVBAHA.120.314378","article-title":"Cancer therapy-associated thrombosis","volume":"41","author":"Grover","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.blre.2025.101257_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103581","article-title":"Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: a systematic review and meta-analysis","volume":"171","author":"Tjepkema","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2025.101257_bb0680","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1053\/j.gastro.2013.10.012","article-title":"Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy","volume":"146","author":"Afdhal","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.blre.2025.101257_bb0685","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJMoa1110709","article-title":"Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia","volume":"367","author":"Afdhal","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101257_bb0690","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.dld.2018.06.005","article-title":"Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: a meta-analysis","volume":"51","author":"Loffredo","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.blre.2025.101257_bb0695","first-page":"642","article-title":"Post-marketing study of recombinant human thrombopoietin injection for adverse drug reaction monitoring","volume":"34","author":"Hou","year":"2015","journal-title":"Chin J New Drugs Clin Remedies"},{"key":"10.1016\/j.blre.2025.101257_bb0700","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/blood.V87.9.3615.bloodjournal8793615","article-title":"A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy","volume":"87","author":"Gordon","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101257_bb0705","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.exphem.2009.06.011","article-title":"Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function","volume":"37","author":"Erhardt","year":"2009","journal-title":"Exp Hematol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T01:36:00Z","timestamp":1740360960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":141,"alternative-id":["S0268960X25000025"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101257","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of thrombopoietic agents in cancer therapy-induced thrombocytopenia: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101257","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101257"}}